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Autophagy and mTOR mediated regulation of cytoplasmic homeostasis and podocyte 
size are two key cellular mechanisms that underpin the integrity of the renal filtration 
barrier. Investigations of various tissues and cell lines support the notion that mTOR 
suppresses autophagy. In a translational context it has been proposed that induction of 
autophagy through the inhibition of mTOR activity could be of clinical benefit. 
Unexpectedly, we report that genetic manipulation of mTOR activity does not influence 
the high levels of basal autophagy in podocytes either in vitro or in vivo. Instead we 
present data showing that autophagy in podocytes is primarily controlled by AMP-
activated protein kinase (AMPK) and Unc-51-like kinase 1 (ULK1). Pharmacologic 
inhibition of mTOR further reveals that the uncoupling of mTOR activity and autophagy 
is time-dependent. Thus, our data reveal a novel cell-specific mechanism, which permits 
concurrent mTOR activity as well as high basal autophagy rates in podocytes. 
Therefore, we advocate manipulating the AMPK-ULK1 axis rather than inhibiting mTOR 












Worldwide, glomerular diseases are the leading cause for end-stage renal disease 
(ESRD) requiring hemodialysis treatment.1 Due to the increase of ESRD prevalence, 
understanding glomerular biology is critical for future targeted pharmacological 
treatments to maintain the glomerular filtration barrier - a unique structure 
characterized by a complex three-layered composition of podocytes, glomerular 
basement membrane and endothelial cells.1,2 Podocytes are highly specialized 
epithelial cells with long interdigitating foot processes enclosing the glomerular 
capillaries and their progressive loss is associated with proteinuria and renal 
failure.2,3,4,5  
Diminution in podocyte number due to cellular or tissue insult cannot be reconstituted 
by existing cells due to their post-mitotic nature. Their ability to survive depends on 
their capacity to endure cellular stress. Macroautophagy (later referred to as 
autophagy) has been implicated as the major cellular maintenance mechanism of 
podocytes characterized by removal of dysfunctional organelles and misfolded 
proteins by enclosure within double membrane vesicles called autophagosomes and 
their subsequent lysosomal fusion and degradation.5-9 In brief, autophagy is initiated 
at an endoplasmic reticulum subdomain called the omegasome – a membrane 
compartment rich in phosphatidylinositol-3-phosphate.10 After nucleation the 
phagophore, an isolation membrane and autophagosome precursor, is elongated 
using a lipid supply from various cellular membrane compartments.11,12 At the same 
time, cytosolic microtubule-associated protein 1 light chain 3 (LC3-I) is conjugated to 
phosphatidylethanolamine and integrated into the autophagosomal membrane (the 
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lipidated form referred to as LC3-II, a key biochemical marker for autophagy).13,14 
Further phagophore elongation is driven by a complex interplay of WD repeat 
phosphoinositide interacting proteins as well as the autophagy-related (ATG) protein 
8 and autophagy-related protein 12 conjugation system.15-21 
Phagophore initiation, and thereby the initial step of autophagosome formation, is 
promoted by two complexes – the unc-51-like autophagy activating kinase 1 (ULK1) 
complex and the class III phosphoinositide 3-kinase – Beclin1 complex.  In particular, 
the ULK1 complex serves as a hub integrating upstream signals to regulate 
autophagic activity.22-26 
In podocytes, autophagy block by cell-specific deletion of Atg5 (coding for a protein 
important for phagophore membrane elongation) leads to proteinuria and features of 
accelerated ageing as well as massively increased glomerular disease susceptibility 
(see ref. 5) e.g. towards diabetic nephropathy (DN) and focal segmental 
glomerulosclerosis (FSGS).6,27,28 Furthermore, podocyte maintenance is safeguarded 
by the mechanistic target of rapamycin (mTOR) pathway known to inhibit autophagy. 
24,25,29 Podocytes utilize mTOR signaling for programs of cellular hypertrophy in 
response to cellular stress as observed in DN.30 Both, impaired as well as 
hyperactive mTOR signaling results in proteinuria and podocyte loss.29,31,32 
mTOR is a phosphatidylinositol 3-kinase (PI3K)-like serine/threonine protein kinase 
that is evolutionarily highly conserved and functions in two multiprotein complexes. 
mTOR complex 1 (mTORC1) mediates most of the known functions of the pathway 
like cellular growth and proliferation via substrates that include S6 kinase (p70S6k) 
and 4E-binding protein 1 (4E-BP1). Moreover, mTORC1 is the best characterized 
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repressor of autophagy (see ref. 33), inhibiting this process by phosphorylating 
ULK1.25  
That podocytes use both pathways – high basal autophagy levels as well as 
fluctuating mTOR activity – at the same time, appears to be paradox in the light of 
the known inhibitory function of mTOR on autophagy. To investigate podocyte-
specific regulation of autophagy we applied in our present study genetic and 
pharmacological in vitro and in vivo models to comprehensively determine the impact 
of mTOR on podocyte autophagy and to elucidate time-dependent effects of mTOR 
kinase inhibition on autophagy regulation.  
Results 
Podocytes exhibit high levels of basal autophagy and autophagic flux 
To assess basal autophagy, we analyzed autophagosome formation in vivo in adult 
(4-month-old) GFP-LC3 transgenic mice using LC3 as a marker of autophagy. High 
numbers of autophagosomes were found in the glomeruli, but were rarely found in 
the tubular compartment (Fig. 1A). Intravital two-photon microscopy confirmed high 
numbers of autophagosomes in podocytes under in vivo conditions (Fig. 1B). 
Tandem fluorescent protein tagged LC3 (RFP-GFP-LC3) allows monitoring 
autophagic flux based on differential pH stability of RFP and GFP.34 To determine the 
amount of de novo formed autophagosomes and the flux towards lysosomal 
degradation, we analyzed autophagosomes in vivo in 4-month-old transgenic 
GFP/RFP-LC3 mice.35 Higher numbers of GFP+RFP+ and RFP+ puncta could be 
detected in podocytes compared to tubular cells (Fig. 1C, 1D and S1A). The number 
of RFP+ puncta was comparable with that found in liver tissue (Fig. S1B and S1C), 
also known for high basal activity in autophagy (for reviews, see refs. 36 and 37). 
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Autophagic flux in GFP-LC3 mice was additionally determined by quantifying 
autophagosome numbers in the presence of inhibitors of lysosomal degradation.38,39 
In vivo assessment of autophagosomes revealed autophagosome accumulation in 
response to chloroquine indicating high autophagic flux toward lysosomal 
degradation and high levels of de novo autophagosome formation in podocytes 
compared to tubular cells (Fig. 1E). Furthermore, autophagic flux in podocytes was 
found to be even higher than in liver tissue (Fig. S1D and S1E). In vitro podocytes 
showed higher levels of autophagy as compared to tubular cells indicated by higher 
levels of LC3-II and lower levels of the autophagy substrate SQSTM1   (Fig. 1F and 
1G). Also, autophagic flux was higher in podocytes than in tubular cells (Fig. S1F 
and S1G). Interestingly, the activity of mTORC1 was significantly elevated in 
podocytes as determined by phosphorylation of the p70S6k substrate ribosomal 
protein S6 (pS6) and phosphorylated 4E-BP1 (Fig. 1F and 1G). Together, these 
results indicate that podocyte exhibit an unusual concomitant autophagic flux and 
elevated mTORC1 activity.  
Basal autophagy is independent of mTOR activity in podocytes 
We next determined levels of autophagy in podocyte-specific genetic models of 
mTORC1 hypo- and hyperactivation. We generated mice bearing a podocyte-specific 
knockout for the gene coding for the regulatory-associated protein of mTOR (Raptor), 
an essential component of mTORC1, by mating Raptor-floxed mice (Raptor fl/fl) with 
mice expressing Cre recombinase under the control of the Podocin (Nphs2) promoter 
(Fig. 2A).29,40 To hyperactivate mTORC1 in podocytes, we generated mice lacking 
tuberous sclerosis 1 (Tsc1, coding for an upstream repressor of mTORC1) by using 
the same podocyte-specific deletion line (Fig. 2A). To monitor autophagosome 
formation, we crossed these mice to a GFP-LC3 reporter strain (Fig. S2A). 41 
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Surprisingly, the two genetic models of mTORC1 hypo-and hyperactivation showed 
no difference in the number of autophagosomes compared to WT (Fig. 2B – 2E). 
Next we assessed LC3-II and SQSTM1 levels in glomeruli harvested from these 
models using magnetic bead perfusion for high purity (Fig. 2F and 2G). There was 
no significant difference in LC3-II or SQSTM1 levels indicating similar levels of basal 
autophagy in Raptor or Tsc1 deficient podocytes. The podocyte-specific knockout for 
Raptor was confirmed in these glomerular lysates (Fig. 2F). Since podocytes count 
for approximately 40% of all glomerular cells the low remaining levels of RAPTOR 
are caused neighboring mesangial cells not affected by Nphs2-Cre-mediated Raptor 
deletion.42,43  As expected, Raptor deficiency lowered mTORC1 activity, which was 
indicated by lower levels of pS6 and lower levels p4E-BP1 (Fig. 2F and 2G). Staining 
for pS6 revealed podocyte specific inhibition of mTORC1 (Fig. S2B). 
Correspondingly, mTORC1 hyperactivation due to deletion of Tsc1 was indicated by 
increased phosphorylation of mTORC1 downstream targets S6 and 4E-BP1 (Fig. 2F 
and 2G). 
Assessment of autophagic flux in glomeruli obtained from mice with podocyte-
specific Raptor or Tsc1 deletion with and without chloroquine treatment revealed no 
difference compared to WT (Fig. S2C). To exclude developmental effects of Raptor 
deficiency on podocyte autophagy, we assessed autophagy in an inducible model of 
podocyte-specific Raptor deletion by crossing Raptor fl/fl mice to Nphs2-rtTA; tetO-
Cre mice (Fig. S2D). After induction of podocyte-specific Raptor deletion, we 
confirmed the knockout and determined LC3-II. Again, WT and Raptor-deficient 
glomeruli showed no significant difference in LC3-II (Fig. S2E and S2F).  
For primary podocyte analysis, we crossed Raptor-floxed mice (Raptor fl/fl) and Tsc1-
floxed mice (Tsc1 fl/fl) with podocyte- specific Cre expression to a Tomato/EGFP 
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reporter strain (Fig. 3A and 3B). This permits the isolation of primary podocytes by 
fluorescence activated cell sorting (FACS) for in vitro culture (Fig. S2G). Due to the 
suppression of mTORC1, primary Raptor deficient podocytes showed almost no 
proliferative capacity. However, they displayed comparable numbers of LC3 puncta 
in comparison to WT podocytes (Fig. 3C and 3D). Profiling of key molecules that 
regulate autophagy through Western blotting was not possible due the paucity of 
Raptor deficient podocytes. Instead we applied the proximity ligation assay technique 
to monitor autophagy. Herein we assessed the association between LC3 and 
SQSTM1 which is critical to the formation of the autophagosome (see ref. 44) (Fig. 
3E). Again, there was no detectable difference in autophagosome number between 
Raptor deficient cells and their control counterparts (Fig. 3F and 3G) - indicating no 
activation of autophagy despite mTORC1 suppression. 
Primary podocytes with mTORC1 hyperactivation due to Tsc1 deficiency showed 
similar numbers of LC3 puncta (Fig. 3H and 3I) and no difference in LC3-II or 
SQSTM1 levels compared to WT despite high mTORC1 activity (indicated by 
increased pS6/S6 ratio and p4E-BP1/4E-BP1 ratio) (Fig. 3J and 3K). Autophagic flux 
was also comparable in WT versus Tsc1 deficient podocytes (Fig. S2H, S2I and 
S2J).    
AMPK controls autophagy in podocytes 
To investigate AMPK activity in podocytes we first assessed phosphorylation of 
AMPK at Thr172 (pAMPKThr172) and of its substrate acetyl-CoA carboxylase at 
Ser79 (pACCSer79). In tissue sections, the highest levels of pACC were found in 
glomeruli of mice with podocyte specific deletion of Tsc1, whereas Raptor deficient 
podocytes displayed low pACC levels (Fig. 4A, quantification in S3A).  Accordingly, 
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significantly increased levels of phosphorylated AMPK and pAMPK/AMPK ratio were 
found in glomerular lysates obtained from mice with podocyte specific Tsc1 knockout 
(Fig. 4B and 4C). Impaired mTORC1 formation (due to Raptor deficiency), however, 
was associated with significantly decreased pAMPK levels and lower pAMPK/AMPK 
ratio compared to WT (Fig. 4B and 4C).  
Next we assessed phosphorylation of the key autophagy regulator ULK1 by AMPK 
and mTORC1. While Ser757 is a target site of mTORC1 inhibiting ULK1 activity, 
Ser555 and Ser317 are target sites of AMPK with an activating effect on ULK1 and 
autophagy.45-47 Glomeruli with podocyte specific Tsc1 deficiency displayed the 
highest pULK1Ser757/ULK1 ratio, whereas impaired mTORC1 formation resulted in 
a significantly decreased pULK1Ser757/ULK1 ratio compared to WT (Fig. 4B and 
4D). pULK1Ser757/ULK1 ratio indicated enhanced or decreased mTORC1 activity, 
respectively, and was in line with our findings on pS6 and p4E-BP1 (Fig. 2F).  AMPK 
driven phosphorylation of ULK1 was significantly increased upon mTORC1 
hyperactivity (pULK1Ser555, pULK1Ser317), whereas pULK1Ser317 was decreased 
in Raptor deficient podocytes compared to WT (Fig. 4D).  
To test if AMPK sustains autophagy in podocytes, autophagy was assessed in vitro 
in primary cultured podocytes treated with the AMPK acitvators 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR) and metformin. Both treatments enhanced 
autophagy as indicated by increased LC3-II and decreased SQSTM1 abundance 
(Fig. 4E and 4F, Fig. S3B). Administration of chloroquine revealed an increase in 
autophagic flux (Fig. S3C and S3D). As expected, AICAR activated AMPK, as 
assessed by pAMPKThr172 and ULK1 phosphorylation at the AMPK target site 555 
(Fig. 4E, 4G and 4H). Yet, mTORC1 activity was also suppressed by AICAR, as 
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shown by decreased phosphorylation of S6. mTORC1 inhibition might contribute to 
enhanced autophagy in AICAR treated podocytes.  
AMPK stimulates autophagy independently of mTORC1 activity 
To further test the role of mTORC1 in AMPK-induced autophagy, primary podocytes 
lacking Tsc1 and corresponding WT podocytes were treated with AICAR in vitro. 
AICAR increased autophagy as determined by increased LC3-II and decreased 
SQSTM1 (Fig. 5A and 5B). Chloroquine administration revealed increased 
autophagic flux (Fig. S3D and S3E). Autophagy induction due to AICAR was 
comparable in Tsc1 deficient and WT conditions (Fig. 5A and 5B, S3D and S3E). 
Compared to WT, Tsc1 deficient podocytes treated with vehicle showed at baseline 
higher levels of AMPK activation as indicated by increased pAMPK/AMPK ratio (Fig. 
5A and 5B). AICAR enhanced AMPK phosphorylation at Thr172, and ULK1 was 
phosphorylated at the known AMPK phosphorylation sites Ser317 and Ser555 (Fig. 
5A and 5B). The mTORC1- dependent inhibitory phosphorylation site Ser757 slightly 
decreased due to AICAR exposure in WT and Tsc1 deficiency and mTORC1 activity 
was reduced as indicated by decreased levels of phosphorylated ribosomal protein 
S6 (Fig. 5A).  
Due to the limited proliferative capacity of Raptor deficient primary podocytes in vitro, 
we chose an in vivo approach to test for mTORC1 independent effects of AICAR on 
autophagy. Therefore, we performed AICAR treatment on mice with a podocyte-
specific deletion of Raptor. Liver lysates revealed systemic AMPK activation (Fig. 
S3F).  In contrast to WT controls, where pS6 slightly decreased after AICAR 
administration, in Raptor deficient podocytes mTORC1 activity could not be further 
suppressed by AICAR (Fig. S3G). Of note, when mTORC1 was inhibited by Raptor 
11 
 
knockout AICAR was able to enhance autophagy, as demonstrated by increased 
LC3 puncta formation (Fig. 5C and 5E) and reduced SQSTM1 abundance (Fig. 5D 
and 5F). Furthermore, glomerular lysates of Raptor deficient mice showed increased 
levels of LC3 conversion compared to untreated mice (Fig. 5G and 5H). We 
conclude that in podocytes AMPK can enhance autophagy when mTORC1 is 
inhibited. 
To determine whether AMPK can also enhance autophagy under conditions of 
mTORC1 hyperactivation in vivo we performed AICAR treatment in mice with 
podocyte specific deletion of Tsc1. AICAR induced autophagy indicated by increased 
glomerular LC3 signal and decreased SQSTM1 (Fig. S4A and S4B, quantification 
in S5A and S5B). AMPK activation by AICAR was confirmed by glomerular pACC 
staining and pACC/ACC ratio obtained from glomerular lysates showing the highest 
pACC levels in Tsc1 deficiency (Fig. S5C, Fig. S5D and S5E).  Autophagy induction 
by AICAR was comparable in mice with podocyte specific Raptor or Tsc1 deficiency 
and WT controls as indicated by LC3 and SQSTM1 (Fig. S4A and S4B, 
quantification in S5B). Thus, we conclude that AMPK enhances autophagy under 
conditions of mTORC1 inhibition or hyperactivation. Therefore, autophagy induction 
by AMPK is mTORC1-independent in podocytes.  
To further confirm the role of AMPK on podocyte autophagy AMPK was inhibited 
using compound C (also known as 6-[4-(2-Piperidin-1-ylethoxy) phenyl]-3-pyridin-4-
ylpyrazolo [1,5-a]pyrimidine), a selective and reversible AMP-kinase inhibitor. 
Compound C inhibited autophagy and autophagic flux in WT and Tsc1 deficiency 
(Fig. S6A and S6B). Pharmacological inhibition of ULK1/2 by MRT68921 (as 
described in ref. 48) decreased podocyte autophagic flux indicating an important role 




Effects of acute and long-term pharmacological inhibition of mTORC1 on 
autophagy 
Since the independence of autophagy from genetic manipulation of mTORC1 activity 
was an unexpected finding and most previous data linking mTORC1 and autophagy 
have been based on pharmacological inhibition of mTORC1, we aimed next to 
compare short-term pharmacological effects to constitutive long-term genetic 
manipulation of mTORC1 activity. To investigate the short-term effect of 
pharmacological suppression of mTORC1, we treated transgenic GFP-LC3 mice with 
rapamycin (Fig. 6A) and assessed autophagosome number. Hereby, autophagy 
levels were increased, indicated by increased numbers of GFP-LC3 puncta (Fig. 6B 
and 6C), higher levels of LC3-II and a decrease in SQSTM1 (Fig. 6D and 6E). 
Expectedly, S6 phosphorylation and pULK1Ser757/ULK1 ratio were reduced (Fig. 
6D and 6E). AMPK was activated as determined by increased pULKSer555 (Fig. 6D 
and 6E). To control the robustness of our experimental readout, mice with podocyte-
specific Atg5-deficiency underwent the same treatment regimen with rapamycin 
without showing any change in autophagy markers (Fig. S6E). Also in mTORC1 
hyperactive conditions (podocyte-specific Tsc1 deletion) short-term treatment with 
rapamycin induced autophagy (Fig. S6F) and increased autophagy flux (Fig. S6G 
and S6H), demonstrating the impact of mTOR signaling pathway in short-term 
regulation of autophagy. In vivo treatment of Tsc1 deficient mice with rapamycin 
reduced glomerular pS6 levels (Fig. S7A) and activated autophagy (Fig. S7B, 
quantified in Fig. S8A and S8B). The effect of rapamycin on autophagy was slightly 
but not significantly lower in Tsc1 deficiency compared to WT potentially due to 
incomplete mTORC1 inhibition. 
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To determine the effects of pharmacological long-term mTORC1 inhibition by 
rapamycin, we treated GFP-LC3 mice with rapamycin for 3 weeks (Fig. 6F). We 
confirmed the efficacy of the treatment through evidencing elevated serum levels of 
rapamycin in treated animals (Fig. 6G). But when autophagy was assessed in 
glomerular lysates and compared to vehicle or short-term treatment we found that 
long-term treatment exhibited no effect on LC3-II or SQSTM1 levels (Fig. 6H and 6I). 
Furthermore neither autophagosome number (Fig. S8C and S8D) nor SQSTM1 
accumulation differed among the long-term treatment group and untreated controls 
(Fig. S8E and S8F). Additionally, analysis of autophagosomes after lysosomal 
inhibition with chloroquine did not reveal any difference among the groups with 
regards to autophagosome number (Fig. S9A and S9B) or SQSTM1 accumulation 
(Fig. S9C and S9D). Direct comparison of LC3 obtained from glomerular lysates of 
short-term and long-term treated mice with and without chloroquine revealed 
increased autophagic flux after short-term treatment but no change after long-term 
treatment compared to vehicle (Fig. S9E, Fig. S9F and S9G). Of note, long-term and 
short-term treatment with rapamycin showed different impact on AMPK activation. 
AMPK was highly activated in the short-term regimen, whereas after long-term 
treatment AMPK activity was lowered compared short-term treated mice or to vehicle 
treated controls (Fig. 6H and S9H). mTORC1 inhibition decreased pULKSer757 
levels in both treatment regimens. Activating phosphorylation of ULK1 at Ser555, 
however, was highly abundant after short-term treatment and lowest after long-term 
treatment (Fig. 6H and S9H).  
To further compare time dependent effects of AMPK activation and mTORC1 
inhibition on autophagy short-term and long-term treatments with AICAR and 
rapamycin were performed and analyzed head to head. Comparison of LC3-II and 
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SQSTM1 in glomerular lysates after 3 days of AICAR and rapamycin treatment, 
respectively, revealed increased autophagy in both treatment conditions (Fig. S10A 
and Fig. S10B). In vitro, AICAR and rapamycin treated primary murine podocytes 
showed active autophagy and increased autophagic flux after 3 days of treatment 
(Fig. S10C). Long-term administration of rapamycin, however, failed to activate 
autophagy and autophagic flux whereas AICAR maintained its pro-autophagic effect 
independent of treatment duration (Fig. S10D). Following rapamycin exposure AMPK 
activity increased after 24h, however, then decreased in a time-dependent manner in 
primary podocytes whereas mTORC1 signaling remains suppressed (Fig. S10E and 
S10F). Long-term pretreatment with rapamycin and AICAR, respectively, followed by 
short-term AICAR or rapamycin exposure demonstrated maintained pro-autophagic 
effects of active AMPK signaling independent from mTORC1 activation state 
corresponding to our findings in Raptor of Tsc1 deficient podocytes treated with 
AICAR (Fig. S11A, S11B and C). In conclusion, we propose that autophagy 
induction by short-term rapamycin treatment is mediated by both mTORC1 inhibition 
and AMPK activation. Both pathways synergistically activate ULK1 and thereby 
induce autophagy (Fig. 7E). After long-term rapamycin treatment, however, AMPK is 
inactive and counteracts the activating signals of mTORC1. Autophagy levels remain 
unchanged (Fig. 7F). Our data demonstrate that the impact of mTORC1 on podocyte 
autophagy is limited to short-term adaptive response and can be overridden by 
AMPK activity at any time suggesting AMPK-ULK1 signalling axis as the higher-





ESRD is a global burden affecting over 2 million people worldwide relying on dialysis 
treatment or undergoing renal transplantation.49,50 Glomerular diseases and diabetic 
nephropathy (DN) are the leading cause for ESRD in developed countries, indicating 
the importance of intact glomeruli and podocytes for maintaining renal integrity.51 
Autophagy has emerged as the key maintenance mechanism in podocytes as 
evidenced in various experimental and human proteinuric kidney diseases such as 
diabetic nephropathy, apolipoprotein L1 (APOL1) associated focal segmental 
glomerulosclerosis (FSGS), FSGS, membranous nephropathy, IgA nephropathy and 
M. Fabry.5,6,28,52,53  While basal autophagy levels are already high,5 it appears that 
further pharmacological activation of autophagy can provide additional beneficial 
effects, e.g. as short term treatment in situations of severe podocyte stress in acute 
inflammatory glomerular diseases. Safety concerns regarding further elevation of 
already high levels of autophagy in podocytes seem to be a minor issue since none 
of the published experimental models of constitutively upregulated autophagy 
exhibited a renal phenotype under basal conditions.54,55 
However, a critical first step is to develop an understanding of the signaling cascades 
that regulate this process in podocytes. 
The mTOR signaling pathway is recognized as the major regulator of autophagy, as 
demonstrated in yeast, drosophila and mammalians.24-26,56,57 mTORC1 inhibits 
autophagy-initiating ULK1 complex by phosphorylating amongst others ULK1 at 
Ser757 in mice (Ser758 of human ULK1) leading to reduced ULK1 kinase activity 
and suppressed autophagy induction. 24-26,45,58 Since stress response of podocytes 
as observed in glomerular disease includes both upregulation of autophagy and 
increased mTORC1 activity, this indicates an uncoupling of mTOR and autophagy in 
these cells.5,29 In line, we observed similar levels of autophagy in genetic models of 
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podocyte-specific mTORC1 hypo- and hyperactivation and under long-term 
pharmacological inhibition of mTORC1 formation, suggesting the existence of an 
additional signaling layer for regulating this important pathway for cellular 
maintenance. Previous studies propose different mechanisms allowing for this 
uncoupling of autophagy and mTORC1 activity or rapamycin action e.g. spatial 
coupling of mTOR and autophagy (see ref. 59) or increased mTORC1 stabilization 
counteracting rapamycin effects under long-term exposure.60 However, in podocytes, 
we identified the AMPK signaling pathway directly regulating ULK1 activity as a key 
regulatory axis governing autophagy in podocytes independent of mTORC1 activity 
and provide first in vivo evidence for this recently proposed mechanism.45-47 
Crosstalk of AMPK and mTOR occurs at different levels of autophagy regulation (for 
reviews, see ref. 61-64). AMPK signaling is proposed to act upstream of mTORC1 with 
low nutrient supply activating AMPK which then activates the TSC complex leading to 
mTORC1 inhibition and autophagy activation (for a review, see 65). Additionally, 
AMPK can directly inhibit mTORC1 activity by phosphorylating RAPTOR.66 More 
downstream, ULK1 acts as a signaling hub orchestrating signaling inputs from 
mTORC1 and AMPK. In response to starvation, ULK1 is rapidly dephosphorylated, in 
particular at the Ser757 mTORC1 target site, leading to autophagy induction.45,58 
Furthermore, phosphorylation of ULK1 at Ser317 and Ser777 by AMPK activates 
autophagy.45 Besides initiating autophagy, the role of ULK1 is even more complex. In 
a feedback loop ULK1 is able to phosphorylate RAPTOR and thereby maintains 
inhibition of mTORC1 if nutrient availability is reduced and autophagy is activated.67 
Furthermore, ULK1/2 is able to phosphorylate all three subunits of AMPK inhibiting 
its activity and thereby acting as a negative feedback regulation of autophagy.68  To 
unravel this complex interplay of AMPK, mTORC1 and ULK1 we combined genetic 
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and pharmacological approaches to identify the major regulatory signaling axis for 
podocyte autophagy regulation. 
In our genetic models AMPK counteracts mTORC1 function in regard to autophagy 
regulation leading to maintained levels of basal autophagy (Fig. 7A and 7B). In 
mTORC1 hypoactivation AMPK activity is found to be decreased (Fig. 7A). Reduced 
inhibitory phosphorylation at ULK1 at Ser757 due to abolished mTORC1 formation is 
outbalanced by reduced activating signal at Ser555 and autophagy levels are 
maintained. These maintained levels of autophagy seem to be in contrast to previous 
studies describing impaired autophagy due to disturbed autophagolysosomal 
reformation in podocytes lacking mTOR.69,70 Complete deletion of mTOR as 
performed in these studies additionally impacts mTORC2 which then might further 
disturb cellular lysosome homeostasis.71,72 In our genetic models, however, 
lysosomal inhibition by chloroquine did not uncover differences in autophagic flux 
compared to WT suggesting limited differential impact of mTORC1 on lysosomal 
function and no critical effect on autophagy refreshment due to mTORC1 in 
podocytes.  
In mTORC1 hyperactivation AMPK is activated thereby driving autophagy (Figure 
7B). AMPK activation might potentially occur due to changes in the cellular metabolic 
state affecting AMP:ATP ratio if Tsc1 is lacking as it has been reported in Tsc1 
deficient macrophages.73 Activating phosphorylations of ULK1 by AMPK compensate 
for inhibitory mTORC1 signal and levels of autophagy finally remain unaffected.  
The impact of AMPK on podocyte autophagy becomes most apparent when AMPK is 
activated by AICAR. Activating sites of ULK1 at Ser317 and Ser555 are 
phosphorylated and active AMPK concomitantly inhibits mTORC1 activity leading to 
18 
 
high levels of autophagy (Fig. 7C). Interestingly, this concomitant mTORC1 inhibition 
turned out to be dispensable for autophagy activation as demonstrated in mice 
bearing a podocyte-specific deletion of Raptor (Fig. 7D). Although autophagy 
activation by AMPK dependent phosphorylation of ULK1 at Ser317 and Ser555 has 
been described in vitro (see ref.45-47), our data now provide the first in vivo evidence 
and point to the important role of ULK1 for autophagy regulation.  
Furthermore, our findings in genetic models of mTORC1 hypo- and hypoactivation 
reflect a time dependent impact of mTORC1 on autophagy regulation (Fig. 7E and 
7D). In contrast to short-term mTORC1 inhibition, long-term treatment with rapamycin 
failed to induce sustained autophagy activation due to reduced activating signals on 
ULK1 by AMPK as observed in mice with podocyte-specific deletion of Raptor. Again, 
AMPK counteracts mTORC1 function in regard to autophagy regulation.  
Thus, our data highlight a tight control by upstream signaling events (i.e. mTORC1 
and AMPK signaling) leading to persistent basal autophagy levels in podocytes. 
Seen at the level of cellular evolution this unique mode of autophagy regulation 
seems to be crucial for the establishment of the particularly highly differentiated and 
long-lived structures of the kidney filter. Next to the detailed genetic manipulation of 
mTOR future studies also including a genetic – and not only pharmacologic 
interference of AMPK signaling - would further deepen the understanding of the role 
of AMPK in this system independent from issues of compound specificity of AICAR or 
compound C or duration of treatment. 
Inducing autophagy in podocytes might be a potential treatment approach to cure or 
at least prevent renal disease. mTOR inhibitors have known autophagy-inducing 
properties; however, there are several concerns about these compounds from a renal 
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perspective. Beside severe systemic effects on the immune system and fertility, 
mTOR inhibitors suppress mTORC1-driven adaptive hypertrophy in podocytes and 
thereby lead to podocyte loss and proteinuria and in some cases even to FSGS.74-79 
Furthermore, our genetic models and different treatment regimens showed that short-
term effects targeting mTORC1 in podocytes failed to induce a sustained activation 
of autophagy. Instead we suggest that AMPK activating agents might provide an 
alternative treatment rationale to prevent podocyte disease, as they are effective in 
inducing autophagy even if mTOR signaling is impaired.  
Due to the tight crosstalk of AMPK and mTORC1 activity in podocytes under 
physiological conditions, targeting downstream molecules like ULK1 might be a 
promising approach to induce autophagy to counteract various glomerular diseases 




Materials and Methods 
Mice 
Mice bearing Tsc1 flox (exons 17 and 18) or Raptor flox alleles (exon 6) have been 
previously reported.31,80,81 Podocin (Nphs2)-Cre+ mice were provided by L. Holzman 
(Renal, Electrolyte and Hypertension Division, University of Pennsylvania School of 
Medicine, Philadelphia, PA, USA).40 Raptor-floxed mice (Raptor fl/fl) and Tsc1-floxed 
mice (Tsc1 fl/fl) were crossed with Nphs2-Cre+ mice to generate podocyte-specific 
Raptor or Tsc1 knockout mice (Raptor fl/fl;Nphs2-Cre+, RaptorΔpod, Tsc1 fl/fl;Nphs2-
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Cre+, Tsc1Δpod, respectively). WT;Nphs2-Cre+ and Tsc1 fl/fl;Nphs2-Cre-  or Raptor 
fl/fl;Nphs2-Cre- littermates served as controls. Tsc1Δpod mice and RaptorΔpod mice were 
subsequently crossed to GFP-LC3 transgenic mice, which have been previously 
reported.41 All mice were crossed on a pure C57BL/6 background which is known to 
be relatively resistant to kidney injury. To focus on signaling effects on autophagy in 
intact podocytes RaptorΔpod, Tsc1Δpod and WT mice were harvested at the age of 2 
weeks, i.e. a time point prior to the development of proteinuria to avoid other severe 
phenotypic effects due to Raptor or Tsc1 knockout secondarily affecting autophagy.  
Nphs2-rtTA;tetO-Cre+ mice were provided by S. Quaggin (Samuel Lunenfeld 
Research Institute, Mount Sinai Hospital, University of Toronto, Canada).82 To 
generate doxycycline-inducible podocyte-specific Raptor knockout mice (Raptor 
fl/fl;Nphs2-rtTA;tetO-Cre+) Raptor-floxed mice (Raptor fl/fl) were crossed with Nphs2-
rtTA;tetO-Cre+ mice. TetO-Cre- littermates served as a control. For the induction of 
Raptor deletion, 12-week-old Raptor fl/fl;Nphs2-rtTA;tetO-Cre+ mice received 
doxycycline (Sigma-Aldrich, D9891) via drinking water (2 mg/ml with 5% sucrose, 
protected from light) for a total of 14 days. 
Mice bearing an Atg5 flox allele (flanked exon 3) have been previously reported.83  
Atg5 fl/fl mice were crossed with Nphs2-Cre+ mice to generate podocyte-specific Atg5 
knockout mice (Atg5 fl/fl;Nphs2-Cre+, Atg5Δpod). WT;Nphs2-Cre+ and Atg5 fl/fl;Nphs2-
Cre-  littermates served as controls.    
To monitor autophagic flux, GFP/RFP-LC3 mice were sacrificed after 16 weeks. For 
a review, see ref. 35. To assess autophagic flux in vivo, GFP-LC3 mice were 
harvested 4h after chloroquine (Cq) administration i.p. 100 mg Cq/kg body weight 
(BW) (Sigma-Aldrich, C6628).  
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AICAR treatments have been performed with 500 mg/kg BW 24h and 4h before 
harvest (see ref. 84). For rapamycin treatment mice received either 4 or 10 mg/kg BW 
for long term (3 weeks) or short term (3 days) treatment, respectively. Different doses 
were used due to pharmacokinetics (loading dose for short term use).85 Treatments 
have been performed in Tsc1 fl/fl;Nphs2-Cre+, Raptor fl/fl,Nphs2-Cre+ and ATG5 
fl/fl;Nphs2-Cre+ mice and corresponding controls at the age of 2 weeks (no further 
phenotype at this time point). GFP-LC3 and GFP/RFP-LC3 mice were 4 months old if 
not mentioned otherwise. Rapamycin and AICAR were purchased from Sigma 
Aldrich and Santa Cruz, respectively, and both administered i.p.  
To isolate primary podocytes Raptor fl/fl;Nphs2-Cre+ and Tsc1 fl/fl;Nphs2-Cre+ were 
further crossed to Tomato/EGFP reporter mice. Gt(ROSA)26Sortm4(ACTB-
tdTomato,-EGFP)Luo/J mice were purchased from Jackson Laboratory (Bar Harbor, 
ME). Raptor fl/fl;Tomato/EGFP;Nphs2-Cre+ and Tsc1 fl/fl;Tomato/EGFP;Nphs2-Cre+ 
and WT;Tomato/EGFP; Nphs2-Cre+ were chosen for primary cell isolation. All animal 
studies were approved by the Committee on Research Animal Care 
Regierungspraesidium Freiburg and by INSERM according to the French veterinary 
guidelines respectively. 
Primary Cell Isolation and Cultivation 
Isolation of primary podocytes was performed as recently described.86 To specifically 
label podocytes, conditional mouse lines were crossed to a well-established reporter 
mouse strain.87 Expression of Cre-recombinase results in specific activation of EGFP 
in targeted cell populations.  
To generate primary podocytes, first glomeruli were isolated from non-proteinuric 12 
– 14 day old pups and cultivated in standard podocyte culture medium (RPMI 1640 
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supplemented with 10% fetal calf serum (FCS), penicillin/streptomycin and 
insulin/transferrin/selenite, all from Roche Diagnostics). After 5 days of expansion, 
cells were trypsinized and transferred to HBSS (Hanks Buffered Salt Solution, Gibco 
Life Technologies by Invitrogen, #14025092) supplemented with 0.1 % bovine serum 
albumin (Serva, #11930). Cell suspension was then sorted using FACS (MoFloTM cell 
sorter, Beckmann Coulter) and only EGFP positive cells were further cultivated. 
Cultivation was performed using standard podocyte culture medium and cells were 
plated on collagen IV (Sigma-Aldrich) coated flasks or dishes (all Corning). 
Primary podocytes were treated with AICAR 1mM for 24h. To inhibit mTORC1 in vitro 
podocytes were treated with rapamycin (Sigma-Aldrich) 1 µM for 6h. Compound C 
(Sigma-Aldrich) was applied at a dose of 5 µM for 2h. ULK1/2 inhibition was achieved 
by using MRT 689211 (Tocris) at 10µM for 12h (see ref. 48).  
Staining of primary podocytes 
After FACS procedure, cells were seeded on collagen coated cover slips. 24 h later 
cells were fixed with paraformaldehyde and stained with mouse anti-LC3 (MBL, mAb 
M152-3). 
Immunofluorescence staining 
Kidneys frozen in Tissue-Tek OCTTM (Sakura) were cyrosectioned at 5 μm (Leica 
Kryostat). Sections were fixed with 4% paraformaldehyde. Non-specific protein 
binding was blocked with PBS containing 5% BSA. Sections were incubated for 1 
hour with primary antibodies (rat anti-nidogen/entactin (Novus, NBP1-97001), rabbit 
anti-GFP (Biozol/MBL, #598)). After washing with PBS, fluorophore-conjugated 
secondary antibodies (Invitrogen) were applied for 30 min.  
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For paraffin sections, kidneys were fixed in 4% paraformaldehyde, embedded in 
paraffin, and cut in 3 μm. After dehydration, antigen heat retrieval was performed at a 
pH of 6.  Blocking was performed using PBS containing 5% BSA. Sections were 
incubated for 1 h with primary antibodies (rabbit anti-LC3B (Cell signaling, #2775), 
guinea pig anti-SQSTM1 (Progen, GP62-C), rabbit anti-pS6 Ser235/236 (Cell 
signaling, #4857), rabbit anti-phospho-acetyl-CoA carboxylase Ser79 (Cell signaling, 
#3661), rabbit anti-NPHS2 (Podocin, Sigma P0372), guinea pig anti-NPHS1 
(Nephrin, Progen GP-N2). After washing with PBS, fluorophore-conjugated 
secondary antibodies (Invitrogen) were applied for 30 min. Images were taken using 
a Zeiss laser scan microscope or a Zeiss fluorescence microscope equipped with a 
20 × and a 63 × water immersion objective. Signal was quantified using Image J out 
of 30 glomeruli per mouse if not mentioned otherwise. For the assessment of pACC 
signal integrated density was normalized to the intensity observed in WT glomeruli.   
In vivo two-photon assessment of autophagy 
4-month-old GFP-LC3 mice were anaesthetized with ketamine (100 mg/kg) and 
xylazine (10 mg/kg). After placing a tracheal tube and cannulating the jugular vein 
70kDa Texas red dextran was injected to label the vasculature. The left kidney was 
exposed by a flank incision and the animal then further placed on the microscope 
stage as described.88,89 Images have been acquired using inverted Zeiss LSM710 
NLO multiphoton confocal fluorescence microscope.  
Glomerular isolation and antibodies used for Western blot 
Glomeruli of non-proteinuric 12 – 14 days old mice were isolated using DynabeadTM 
perfusion (Thermo Fisher Scientific, described in refs. 90,91) and were glass-glass 
homogenized in lysis buffer (RIPA buffer) 92. After centrifugation (15,000 g for 15 
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minutes at 4°C), protein concentration was determined by BCA-Assay (Pierce). Equal 
amounts of protein were separated by SDS-PAGE. Following antibodies were used 
for Western blot: mouse anti-β-actin (Sigma-Aldrich, mAb A5441), mouse anti-α 
tubulin (Sigma Aldrich, mAb T6199), rabbit anti-ULK1 (Cell signaling, #8054), rabbit 
anti-pULK Ser757 (Cell signaling, #6888), rabbit anti-pULK1 Ser555 (Cell signaling, 
#5869), rabbit anti-pULK1 Ser317 (Cell signaling, #6887), rabbit anti-AMPKα (Cell 
signaling, #5381), rabbit anti-pAMPKα  Thr172 (Cell signaling, #4188), guinea pig 
anti-SQSTM1 (Progen, GP62-C), rabbit anti-LC3B (Cell signaling, #2775), rabbit anti-
S6 (Cell signaling, #2217), rabbit anti-pS6 Ser235/236 (Cell signaling, #4857), rabbit 
anti-Raptor (Cell signaling, #2280), rabbit anti-phospho-acetyl-CoA carboxylase 
Ser79 (Cell signaling, #3661), rabbit anti-4E-BP1 (Cell signaling, #9452), rabbit anti-
phospho-4E-BP1 Thr37/46 (Cell signaling, #2855). 
 
 
Immortalized human podocytes 
Podocytes were kindly provided by Moin Saleem (Bristol, UK) and transduced to 
stably express GFP-LC3 via lentiviral expression vector (kind gift of Noboru 
Mizushima, Department of Biochemistry and Molecular Biology, University of Tokyo, 
Japan). Podocytes were cultured as previously described (see ref. 93) and seeded in 
RPMI 1640 supplemented with 10% FCS, insulin/transferrin/selenite, 
penicillin/streptomycin (all from Roche Diagnostics), pyruvate, 100x minimal essential 
medium and HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer (all 
Life technologies). When cells had grown to 60% confluence differentiation was 
induced at 37°C for 10–14 days. Cultured human podocytes were fully differentiated 




Immortalized human proximal tubular cells 
HK 2 cells were purchased from ATCC and transduced to stably express GFP-LC3 
via lentiviral expression vector (kind gift of Noboru Mizushima, University of Tokyo). 
Cells were cultured as described.94 
 
 
Proximity Ligation Assay 
Proximity ligation assay (PLA) was performed following the manufacturer`s 
instructions (Olink Bioscience). In brief, primary podocytes were seeded on Collagen 
IV coated diagnostic microscope slides (8 well, 6 mm, Thermo Scientific). After 24h 
cells were fixed with paraformaldehyde and stained with anti LC3 (MBL, mouse, mAb 
M152-3) and SQSTM1 (Santa Cruz, rabbit pAb, #5114). PLA was performed using 
Duolink® In Situ PLA Probe Anti-Mouse PLUS and using Duolink® In Situ PLA® 
Probe Anti-Rabbit MINUS following the manufacturer`s instructions. Imaging was 
performed using a Zeiss Axiovert 200M microscope, equipped with AxioCam MRc5 
digital video camera and ApoTome immunofluorescence apparatus (Carl Zeiss SpA, 
Arese, Italy). Images were recorded using AxioVision software 4.3 and analyzed by 
Image J. Signal of 40 cells were analyzed per experiment; 3 experiments were 
performed. 
Sirolimus serum levels 
Serum levels of sirolimus (rapamycin) were obtained using LC-MS/MS. Analysis was 
kindly performed by Division of Clinical Chemistry, Department of Medicine, 






Data were expressed as the mean ± standard deviation (SD). All experiments were 
performed at least 3 times. Statistical comparisons were performed with the program 
Excel using 2-tailed Student`s t test and with Graphpad Prism for ANOVA (Fig. S5F, 
Fig. S7A, Fig. S7B, Fig. S8F and S8G), respectively. Differences with p ≤ 0.05 were 
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Fig. 1: Podocytes exhibit high levels of basal autophagy and autophagic flux. (A) 
Representative images obtained from cryosections of 4-month old GFP-LC3 mice 
stained for the basement membrane marker entactin/nidogen (red) and GFP-LC3 
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(green). (B) Two-photon images of glomeruli from GFP-LC3 mice perfused with 
dextran as a marker for glomerular capillaries (in red) displaying autophagosomes in 
vivo (in green, marked with arrow). (C)  Representative images obtained from 
cryosections of 4-month-old GFP/RFP-LC3 mice stained for entactin/nidogen 
(purple). RFP-LC3 and GFP-LC3 fluorescence is endogenous. (D) Quantification of 
(C) out of 30 glomeruli from 3 mice each with surrounding tubular cells (** ≤ 0.01, * ≤ 
0.05). (E) Cryosections displaying glomeruli (upper panel) and tubular system (lower 
panel) stained for entactin/nidogen (red) and GFP-LC3 (anti-GFP antibody, green) in 
4-month-old WT mice with and without chloroquine (4h after chloroquine (Cq) 
administration i.p. 100 mg Cq/kg BW). (F) Western blot from immortalized human 
podocyte cell line and proximal tubular cell line (HK2) for mTORC1 downstream 
targets and LC3 abundance. (G) Densitometry obtained from (F) (** ≤ 0.01). 
Fig. 2: Basal autophagy is independent of mTOR activity in podocytes in vivo. (A) 
Schematic of generating podocyte-specific deletion of Raptor or Tsc1 using Nphs2-
Cre mice and Cre-Lox technique. (B) Cryosections from 2-week-old mice bearing 
podocyte-specific knockout for Raptor and transgenic for GFP-LC3 compared to 
GFP-LC3 WT mice (entactin/nidogen in red, GFP-LC3 in green). (C) Quantification of 
GFP-LC3 autophagosomes per glomerular area out of 30 glomeruli each from 3 
mice.  (D) Cryosections from 2-week-old mice bearing podocyte-specific knockout for 
Tsc1  and transgenic for GFP-LC3 compared to GFP-LC3 WT mice (entactin/nidogen 
in red, GFP-LC3 in green). (E) Quantification of GFP-LC3 autophagosomes per 
glomerular area out of 30 glomeruli each from 3 mice.  (F) Western blot out of 
glomerular lysates obtained from 2- week-old mice for mTORC1 downstream targets 
and LC3 and SQSTM1 abundance. (G) Densitometry for LC3-II, SQSTM1 and pS6 
obtained from 3 WT glomerular lysates and 3 glomerular lysates obtained from 2-
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week-old mice bearing a podocyte-specific deletion of Raptor or Tsc1, respectively 
(** ≤ 0.01, * ≤ 0.05).  
 
Fig. 3 Basal autophagy is independent of mTOR activity in podocytes in vitro. (A) 
Schematic of generating mice with a podocyte-specific knockout for Tsc1 additionally 
harboring a Tomato/EGFP allele for primary cell isolation. (B) Schematic of 
generating mice with a podocyte-specific knockout for Raptor additionally harboring a 
Tomato/EGFP allele for primary cell isolation. (C) Primary podocytes with and without 
Raptor deficiency are stained for LC3 in red (green: endogenous fluorescence due to 
Tomato/EGFP reporter and Nphs2-Cre).  (D) Quantification of LC3 signal out of 30 
primary podocytes from 3 mice each. (E) Schematic illustrating proximity ligation 
assay (PLA) for SQSTM1 and LC3. (F) Representative image of primary podocytes 
with and without Raptor and LC3-SQSTM1-PLA signal in red (green: endogenous 
fluorescence due to Tomato/EGFP reporter and NHPS2-Cre). (G) Quantification of 
PLA signal from 30 podocytes obtained from 3 mice each. (H) Primary podocytes 
with and without Tsc1 deficiency stained for LC3 in red (green: endogenous 
fluorescence due to Tomato/EGFP reporter and Nphs2-Cre).  (I) Quantification of 
LC3 signal out of 30 primary podocytes from 3 mice each. (J) Western blot from 
primary podocytes for abundance of LC3, SQSTM1 and mTORC1 downstream 
targets. (K) Densitometry from (I) (** ≤ 0.01).  
Fig. 4: AMPK controls autophagy in podocytes. (A) Representative sections from 2-
week-old mice bearing podocyte-specific deletion of Raptor or Tsc1 and controls 
stained for phosphorylated acetyl-CoA carboxylase Ser79 (pACC) in red and NPHS1 
(green). (B) Western blot out of glomerular lysates obtained from 2- week-old mice 
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(genotype as indicated) for AMPKα and ULK1 and respective phosphorylation sites. 
(C) Densitometry for pAMPKαThr172 obtained from 3 WT glomerular lysates and 3 
glomerular lysates obtained from 2-week-old mice bearing a podocyte-specific 
deletion of Raptor or Tsc1, respectively (** ≤ 0.01, * ≤ 0.05). (D)  Densitometry for 
pULK1Ser757, pULK1Ser555 and pULK1Ser317 obtained from 3 WT glomerular 
lysates and 3 glomerular lysates obtained from 2-week-old mice bearing a podocyte-
specific deletion of Raptor or Tsc1, respectively (** ≤ 0.01, * ≤ 0.05). (E) Western blot 
from primary podocytes treated with AICAR (1mM) for the time indicated (12h or 24h) 
to assess the abundance of pULK1Ser555, pAMPKαThr172 and pS6Ser235/236. (F-
H) Densitometry from (E) (** ≤ 0.01, * ≤ 0.05). 
Fig. 5: Activation of AMPK stimulates autophagy independently of mTORC1 activity. 
(A) Western blot from Tsc1-deficient podocytes and corresponding WT controls with 
and without AICAR treatment (1 mM, 24h) to assess the abundance of 
phosphorylated forms of ULK1 and AMPK as indicated. (B) Densitometry from (A) (** 
≤ 0.01, * ≤ 0.05). (C) Representative section from 2-week-old mice bearing podocyte-
specific deletion of Raptor with and without AICAR treatment (500 mg/kg BW 24h 
and 4h before harvest) stained with LC3 (red) and NPHS1/nephrin in green. (D) 
Representative section from 2-week-old mice bearing podocyte-specific deletion of 
Raptor with and without AICAR treatment (500 mg/kg BW 24h and 4h before harvest) 
stained with SQSTM1 (red) and NPHS1/nephrin in green. (E) Quantification of LC3 
puncta per glomerular area (n = 3 each, 30 glomeruli counted per mouse, * ≤ 0.05).  
(F) Quantification of SQSTM1 puncta per glomerular area (n = 3 each, 30 glomeruli 
counted per mouse, * ≤ 0.05). (G) Western blot from glomerular lysates from 2-week-
old mice bearing podocyte-specific deletion of Raptor with and without AICAR 
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treatment (500 mg/kg BW 24h and 4h before harvest) to assess the abundance of 
LC3-II. (H) Densitometry from (G) (* ≤ 0.05). 
Fig. 6: Effects of acute and long-term pharmacological inhibition of mTORC1 activity 
on autophagy. (A) Schematic of the short-term treatment regimen (rapamycin vs. 
vehicle, n = 5 each, rapamycin dose: 10 mg/kg BW i.p. for 3 days). (B) Quantification 
of GFP-LC3 autophagosomes per glomerular area out of 30 glomeruli each from 5 
mice per group (vehicle vs. rapamycin). (C) Representative cryosections from 16-
week-old mice transgenic for GFP-LC3 with and without rapamycin treatment 
(entactin/nidogen in red, GFP-LC3 in green, rapamycin dose: 10 mg/kg BW i.p. for 3 
days). (D) Representative Western blot from glomerular lysates from rapamycin and 
vehicle treated mice (WT mice, n = 3 each, rapamycin dose: 10 mg/kg BW i.p. for 3 
days). (E) Densitometric quantification of (D) (** ≤ 0.01, * ≤ 0.05). (F) Schematic of 
the long-term treatment regimen (rapamycin dose: 4 mg/kg BW i.p. for 3 weeks). (G) 
Quantification of serum levels of rapamycin (n = 6 each) (*** ≤ 0.001). (H) 
Representative Western blot from glomerular lysates from rapamycin long-term, 
short-term and vehicle treated mice. (I) Densitometry from 3 glomerular lysates of 
each treatment and vehicle controls for LC3-II, SQSTM1 and pS6Ser235/236 (** ≤ 
0.01).  
Fig. 7: Activation of AMPK stimulates autophagy independently of mTOR activity. (A) 
AMPK activity is reduced if mTORC1 signaling is genetically impaired (activating 
phosphorylation sites at ULK1 are displayed in green, inhibitory sites are in red). (B) 
Inhibitory signals on ULK1 by genetically induced mTORC1 hyperactivity are 
compensated by active AMPK signaling. (C)  Pharmacological activation of AMPK is 
able to induce autophagy in podocytes by activating ULK1. (D) mTORC1 can be 
bypassed in autophagy regulation as it occurs in the genetic model  of mTORC1 
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inhibition by direct phosphorylation of ULK1 by AMPK. (E)  Short-term treatment with 
rapamycin inhibits mTORC1 activity and activates AMPK leading to increased levels 
of autophagy. (F) Long-term treatment with rapamycin is compensated by reduced 
AMPK signaling in regard to autophagy regulation.   
 
Fig. S1: Podocytes display high levels of basal autophagy. (A) Representative 
images from tubular system of 4-month-old GFP/RFP-LC3 mice (endogenous 
fluorescence). (B)  Representative images from the liver of 4-month-old GFP/RFP-
LC3 mice. (C) Quantification of (A), (B), and Fig.1C out of 50 cells obtained from 3 
different mice (* ≤ 0.05). (D) Liver sections of GFP-LC3 mice with and without 
chloroquine treatment (chloroquine i.p. 100 mg/kg BW for 4h as indicated in Method 
section) stained for GFP-LC3 (green) and nidogen/entactin (red). (E) Western blot 
analysis for the abundance of LC3 from tissue lysates from mice treated with and 
without chloroquine (100 mg/kg BW i.p. for 4h as indicated in Method section). (F) 
Autophagosome formation with and without chloroquine treatment (100 µM, 2 h) in 
an immortalized human proximal tubular cell line (HK2) and human podocytes stably 
expressing GFP-LC3 (in green). (G) Quantification of (F) (* ≤ 0.05). 
Fig. S2: Genetic models of mTORC1 hypo- and hyperactivation and their impact on 
autophagy. (A) Schematic of generating mice with a podocyte-specific deletion of 
Raptor or Tsc1 and transgenic for GFP-LC3. (B) Immunofluorescence staining for 
phosphorylated ribosomal protein S6 Ser235/236 in WT mice and mice bearing 
podocyte-specific deletion of Raptor. (C) Western blot analysis from glomerular 
lysates obtained from WT mice and mice bearing podocyte-specific deletion of 
Raptor or Tsc1, respectively, with and without chloroquine (100 mg/kg BW i.p. for 4h) 
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for the abundance of LC3-I and LC3-II.   (D) Schematic of generating mice with a 
doxycycline-inducible podocyte-specific deletion of Raptor. (E) Western blot analysis 
from glomerular lysates obtained from WT mice and mice after induction of podocyte- 
specific Raptor deletion. (F) Densitometry for LC3-II abundance from 3 samples each 
(induced Raptor deficiency vs. WT). (G) Schematic of obtaining pure primary 
podocyte culture by Tomato/EGFP labeling and cell sorting by FACS. (H) Western 
blot analysis for LC3-II abundance and mTORC1 downstream targets in primary 
cultured podocytes (WT vs. Tsc1-deficient) treated with chloroquine (100 µM, 2 h). (I) 
Western blot analysis for LC3-II abundance in primary cultured podocytes (WT vs. 
Tsc1-deficient) with and without chloroquine treatment (100 µM, 2 h). (J) 
Densitometry of 3 samples each as displayed in (H).  
Fig. S3: Impact of AMPK activation of autophagy. (A) Integrated density of 
glomerular pACC signal obtained from 3 mice of each genotype (WT, Raptor and 
Tsc1-deficient, 20 glomeruli assessed per mouse, * ≤ 0.05). (B) Western blot for LC3-
II abundance and AMPK activation in primary podocytes treated with metformin for 2 
h with the indicated dose. (C) Western blot for LC3-II abundance in primary 
podocytes treated with metformin for 2 h with and without chloroquine (100 µM, 2 h). 
(D) Western blot from lysates obtained from primary podocytes (WT vs. Tsc1-
deficient) treated with AICAR (1mM, 24h) or vehicle with or without chloroquine (100 
µM, 2 h). (E) Densitometry for LC3-II from lysates obtained from primary podocytes 
(WT vs. Tsc1-deficient) treated with AICAR or vehicle with or without chloroquine (3 
samples each, * ≤ 0.05, ** ≤ 0.01). (F)  Western blot out of liver lysates for 
abundance of pAMPKαThr172 and pACCSer79 from mice treated with AICAR (500 
mg/kg BW 24h and 4h before harvest) or vehicle. (G) Immunofluorescence staining 
for phosphorylated ribosomal protein S6 Ser235/236 in WT mice and mice bearing 
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podocyte-specific deletion of Raptor with and without AICAR treatment (500 mg/kg 
BW 24 h and 4 h before harvest). 
 
S4: Effect of AMPK activation by AICAR on autophagy in genetic models of 
mTORC1 hypo- and hyperactivation. (A) Representative sections from 2-week-old 
mice bearing podocyte-specific deletion of Raptor or Tsc1 and corresponding WT 
controls with and without AICAR treatment (500 mg/kg BW 24h and 4h before 
harvest) stained with LC3 (red) and NPHS1/nephrin in green. (B) Representative 
sections from 2-week-old mice bearing podocyte-specific deletion of Raptor or Tsc1 
and corresponding WT controls with and without AICAR treatment (500 mg/kg BW 
24h and 4h before harvest) stained with SQSTM1 (red) and NPHS2 in green.  
S5: Effect of AMPK activation by AICAR on autophagy in genetic models of 
mTORC1 hypo- and hyperactivation. (A) Quantification of Fig. S4A by assessing LC3 
puncta per glomerular area (n = 3 each, 30 glomeruli counted per mouse) with and 
without AICAR treatment (* ≤ 0.05). (B) Quantification of Fig. S4B by assessing 
SQSTM1 puncta per glomerular area (n = 3 each, 30 glomeruli counted per mouse) 
with and without AICAR treatment. (C) Representative sections from 2-week-old mice 
bearing podocyte-specific deletion of Raptor or Tsc1 and corresponding WT controls 
with and without AICAR treatment (500 mg/kg BW 24h and 4h before harvest) 
stained with pACCSer79 (red) and NPHS1/nephrin in green. (D) Western blot from 
glomerular lysates  from 2-week-old mice bearing podocyte-specific deletion of 
Raptor or Tsc1 and corresponding WT controls with and without AICAR treatment 
(500 mg/kg BW 24h and 4h before harvest) for the abundance of pACCSer79, ACC, 
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AMPK and pAMPKαThr172. (E) Quantification of (D) (3 samples each, ** ≤ 0.01, * ≤ 
0.05). 
S6: Effect of mTORC1 inhibition on autophagy. (A) Western blot from lysates 
obtained from primary podocytes (WT vs. Tsc1-deficient) treated with compound C (5 
µM for 2h) or vehicle for AMPK activity and LC3. (B) Western blot from lysates 
obtained from primary podocytes (WT vs. Tsc1-deficient) treated with compound C (5 
µM for 2h) with and without chloroquine (100 µM, 2 h). (C) Primary podocytes treated 
with the ULK1/2 inhibitor MRT68921 (10 µM for 12h) or vehicle with and without 
chloroquine (100 µM, 2 h). (D) Densitometry for LC3-II from lysates as displayed in 
(C) (3 samples each, ** ≤ 0.01, * ≤ 0.05). (E) Western blot from glomerular lysates for 
the abundance of LC3 and pS6Ser235/236 from rapamycin (10 mg/kg BW for 3 
days) and vehicle treated mice bearing podocyte-specific deletion of Atg5. (F) 
Western blot from lysates obtained from primary podocytes (WT vs. Tsc1-deficient) 
treated with rapamycin (1 µM for 6h) or vehicle for mTORC1 downstream targets, 
phosphorylated AMPKα and LC3. (G) Western blot from lysates obtained from 
primary podocytes (WT vs. Tsc1-deficient) treated with rapamycin (1 µM for 6h) with 
and without chloroquine (100 µM, 2 h) for the abundance of LC3. (H)  Densitometry 
for LC3-II from lysates as displayed in (G) (3 samples each, * ≤ 0.05, ** ≤ 0.01).  
S7: Effect of short-term rapamycin treatment on autophagy in genetic models of 
mTORC1 hyperactivation and hypoactivation. (A) Representative sections from 2-
week-old mice bearing podocyte-specific deletion of Raptor or Tsc1 and 
corresponding WT controls with and without rapamycin treatment (10 mg/kg BW for 3 
days) stained for pS6Ser235/236 (red) and NPHS1/nephrin in green. (B) 
Representative sections from 2-week-old mice bearing podocyte-specific deletion of 
Raptor or Tsc1 and corresponding WT controls after rapamycin treatment (10 mg/kg 
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BW for 3 days)  stained for LC3 (red) and NPHS1 in green (left column) or stained for 
SQSTM1 (red) and NPHS2 in green (right column). 
S8: Effect of long-term rapamycin treatment on podocyte autophagy. (A) 
Quantification of Fig. S6A by assessing LC3 puncta per glomerular area (n = 3 each, 
30 glomeruli counted per mouse, ** ≤ 0.01, * ≤ 0.05) after treatment with rapamycin 
(4 mg/kg BW for 3 weeks). (B) Quantification of Fig. S6B by assessing SQSTM1 
puncta per glomerular area (n = 3 each, 30 glomeruli counted per mouse) after 
rapamycin treatment (** ≤ 0.01, * ≤ 0.05). (C) Immunofluorescence staining for GFP-
LC3 (green) and NPHS2 (red) in sections obtained from mice treated with rapamycin 
or vehicle for 3 weeks. (D) Quantification for GFP-LC3 per glomerular area 
(rapamycin n = 3, vehicle n = 4). (E)  Immunofluorescence staining for GFP-LC3 
(green) and SQSTM1 (red) in sections obtained from mice treated with rapamycin or 
vehicle for 3 weeks. (F) Quantification for SQSTM1 per glomerular area (rapamycin n 
= 3, vehicle n = 4). 
S9: Effect of long-term rapamycin treatment on podocyte autophagic flux. Mice were 
treated with rapamycin 4 mg/kg BW for 3 weeks receiving 100 mg/kg BW chloroquine 
4 h before harvest. (A) Sections were stained for GFP-LC3 (green) and NPHS2 (red). 
(B) Quantification of LC3 signal per glomerular area (rapamycin + Cq n = 3, vehicle + 
Cq n = 4) (C) Sections were stained for GFP-LC3 (green) and SQSTM1 (red). (D) 
Quantification of SQSTM1 signal per glomerular area (rapamycin + Cq n = 3, vehicle 
+ Cq n = 4). (E) Western blot from glomerular lysates obtained from mice treated with 
short-term rapamycin treatment (10 mg/kg BW for 3 days) or long-term rapamycin 
treatment (4 mg/kg BW for 3 weeks) or vehicle for the abundance of LC3 and 
SQSTM1 with and without chloroquine (100 mg/kg BW for 4h).  (F) Densitometry for 
LC3-II to ACTIN ratio from 3 samples each (vehicle, rapamycin long-term and short-
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term regimen with and without chloroquine) corresponding to Fig. S8E (** ≤ 0.01).  ).  
(G) Densitometry for SQSTM1 to ACTIN ratio from 3 samples each (vehicle, 
rapamycin long-term and short-term regimen with and without chloroquine) 
corresponding to Fig. S8E (** ≤ 0.01).  (H) Densitometry for pAMPKαThr172 and 
pULK1Ser555 from 3 samples each (vehicle, rapamycin long-term and short-term 
regimen) corresponding to Fig. 6H (** ≤ 0.01, * ≤ 0.05).  
S10: Time dependent effects of rapamycin and AICAR on podocyte autophagy. (A) 
Western blot from glomerular lysates obtained from mice treated with short-term 
rapamycin treatment (10 mg/kg BW for 3 days) or short-term AICAR treatment (500 
mg/kg BW for 3 days) or vehicle for mTORC1 downstream targets, phosphorylated 
AMPKα and LC3. (B) Densitometry for pAMPKαThr172 and LC3 from 3 samples 
each as displayed in (A). (C) Western blot from primary murine podocytes treated 
with rapamycin (1 µM for 3 days) or AICAR (1mM for 3 days) with and without 
chloroquine (100 µM, 2 h) for the abundance of LC3, SQSTM1 and phosphorylated 
ULK1, S6 and AMPKα.  (D) Western blot from primary murine podocytes treated with 
rapamycin (10 nM for 3 weeks) or AICAR (0.2 mM for 3 weeks) with and without 
chloroquine (100 µM, 2 h) for the abundance of LC3, SQSTM1 and phosphorylated 
ULK1, S6 and AMPKα.  (E) Western blot from primary murine podocytes treated with 
rapamycin (1 µM for 3 days or 10 nM for 3 weeks) or AICAR (1mM for 3 days or 0.2 
mM for 3 weeks) for the abundance of phosphorylated S6 and AMPKα. (F) 
Densitometry for pAMPKαThr172 as displayed in (E). 
S11: mTORC1 independent effects of AICAR on podocyte autophagy. (A) Western 
blot from primary murine podocytes pretreated with rapamycin (10 nM for 3 weeks) or 
AICAR (0.2 mM for 3 weeks) followed by rapamycin (1 µM for 3 days) or AICAR 
(1mM for 3 days) with and without chloroquine (100 µM, 2 h) for the abundance of 
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LC3, SQSTM1 and phosphorylated S6 and AMPKα. (B) Western blot from primary 
murine podocytes pretreated with rapamycin (10 nM for 3 weeks) or AICAR (0.2 mM 
for 3 weeks) followed by rapamycin (1 µM for 3 days) or AICAR (1mM for 3 days) for 
the abundance of phosphorylated S6 and AMPKα. (C) Densitometry for 
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